Information Provided By: 
Fly News Breaks for March 27, 2017
AET, EXAS
Mar 27, 2017 | 08:31 EDT
Craig-Hallum analyst Bill Bonello continue to recommend purchase of Exact Sciences (EXAS) as Aetna (AET) coverage reinforces his view that the outlook is stronger than ever. After the latter published an updated colorectal cancer screening policy which now includes coverage of Exact Sciences' Cologuard, the analyst notes that Aetna was "one of the last major holdouts" from a commercial coverage standpoint. Bonello reiterates a Buy rating and $28 price target on Exact Sciences' shares.
News For EXAS;AET From the Last 2 Days
There are no results for your query EXAS;AET
